Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + nimotuzumab
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
toripalimab + nimotuzumab is a combination therapy being investigated for the treatment of oral squamous cell carcinoma. Toripalimab is a humanized IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor, acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. It was developed by Shanghai Junshi Biosciences. Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting tumor cell growth and survival. In a clinical trial led by Peking Union Medical College Hospital, this combination is being evaluated as a neoadjuvant therapy for patients with primary limited-stage oral squamous cell carcinoma prior to radical therapy.
- Brand names
- TuoyiTaixin
- Other names
- toripalimab and nimotuzumab
02
Targets
EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + nimotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + nimotuzumab.